Cagrilintide Research: What 108 Studies Show (2026) | RetatrutideCompare

Cagrilintide — 108 studies indexed on PubMed. Long-acting amylin and calcitonin receptor agonist. Slows gastric emptying and signals satiety via the area postrema. Half-life: ~7 days. FDA status: Investigational (Phase 3 REDEFINE).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Cagrilintide?

There are approximately 108 studies indexed on PubMed that mention Cagrilintide (AM833), based on a search last updated 2026-06-18.

Is Cagrilintide FDA-approved?

FDA status: Investigational (Phase 3 REDEFINE).

How does Cagrilintide work?

Long-acting amylin and calcitonin receptor agonist. Slows gastric emptying and signals satiety via the area postrema.

Long-acting amylin and calcitonin receptor agonist. Slows gastric emptying and signals satiety via the area postrema.

Reference facts

Also known as
AM833
Category
GLP-1 & Metabolic
Mechanism of action
Long-acting amylin and calcitonin receptor agonist. Slows gastric emptying and signals satiety via the area postrema.
Targets
AMY1R, AMY3R, Calcitonin receptor
Indications under research or approved
Obesity (in combination with Semaglutide as CagriSema)
Regulatory status (reference entry)
Investigational (Phase 3 REDEFINE)
Half-life
~7 days
Sequence
KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY
Sequence notes
37-residue long-acting amylin analog with C18 fatty diacid linker; lysine substitutions and disulfide between Cys2-Cys7.
Molecular weight (Da)
3800
Originator / sponsor
Novo Nordisk
First reported
2018

Primary References

Explore research articles about Cagrilintide

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.